treatment of endogenous fungal endophthalmitis

Clicks: 256
ID: 201282
2004
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #90 of 231 articles by views in planta medica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 231 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract

Background. To report clinical findings and treatment possibilities of patients with endogenous fungal endophthalmitis.

Methods. Records of patients with endogenous fungal endophthalmitis treated at Eye Clinic from January 2000 to July 2003 were retrospectively reviewed. Information obtained from the medical record include the patient age, sex, causative organism, ocular treatment, systemic antifungal treatment, complications, length of follow-up and final visual outcome.

Results. 12 patients (13 eyes)were enrolled (9 males, 3 females, age 18 to 35). Clinical signs of infection cleared and visual acuity improved in all 13 eyes.

Conclusions. Pars plana vitrectomy in combination with intravitreal injection of amphotericin B and oral fluconazole is an effective alternative in managament of endogenous fungal endophthalmitis in selected cases.

Reference Key
lumi2004zdravnikitreatment Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Xhevat Lumi;Mojca Globočnik Petrovič
Journal planta medica
Year 2004
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.